Dr. Loppenberg on Benefits of Local Treatment for Metastatic Prostate Cancer

Björn Löppenberg, MD
Published: Monday, Jul 11, 2016


Björn Löppenberg, MD, oncologist, the Henry Ford Hospital, Vattikuti Urology Institute, discusses the impact of local treatment on overall mortality in patients diagnosed with primary metastatic prostate cancer.
 
A retrospective study that looked at 1,400 metastatic prostate cancer patients who received local treatment, found a benefit in survival at 3 years compared to those who did not receive local treatment. The overall survival benefit was 15%. However, the benefit was only seen in patients that had less aggressive prostate cancer and good overall health status, says Löppenberg.
 
There are several potential benefits of local treatment, even in the metastatic setting, says Löppenberg. Local treatment may reduce the metastatic spread and could prevent local problems such as bladder emptying challenges and urinary retention.    
 

Björn Löppenberg, MD, oncologist, the Henry Ford Hospital, Vattikuti Urology Institute, discusses the impact of local treatment on overall mortality in patients diagnosed with primary metastatic prostate cancer.
 
A retrospective study that looked at 1,400 metastatic prostate cancer patients who received local treatment, found a benefit in survival at 3 years compared to those who did not receive local treatment. The overall survival benefit was 15%. However, the benefit was only seen in patients that had less aggressive prostate cancer and good overall health status, says Löppenberg.
 
There are several potential benefits of local treatment, even in the metastatic setting, says Löppenberg. Local treatment may reduce the metastatic spread and could prevent local problems such as bladder emptying challenges and urinary retention.    
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Publication Bottom Border
Border Publication
x